Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

.0 million of debt incurred during October 2007.

As of March 31, 2008, Pharmasset had approximately $63.0 million of cash and cash equivalents and approximately $1.2 million of short-term investments.

"R7128 for the treatment of hepatitis C virus (HCV) continues to demonstrate best-in-class potential based on its safety, efficacy and high barrier to resistance as demonstrated in 4-week Phase 1 clinical trials," stated Schaefer Price, Pharmasset's Chief Executive Officer. "We look forward to continuing the advancement and broadening the scope of this program by exploring additional Phase 1 cohorts, including an R7128 1000mg dose in patients with HCV genotype 1 and an R7128 1500mg dose in patients with HCV genotypes 2 and 3 who have not responded to prior therapy. We and Roche are currently focused on planning a global 12-week Phase 2b combination study of R7128 with Pegasys plus Copegus."

Highlights of the Quarter Ended March 31, 2008

-- Announced preliminary safety and efficacy results of two cohorts (500mg

and 1500mg) in a 4-week combination study of R7128 with Pegasys plus

Copegus for the treatment of HCV.

-- Appointed Herbert J. Conrad as a member of our Board of Directors and

the Nominating and Corporate Governance Committee.

-- Advanced a new series of proprietary nucleoside analogs that have

demonstrated potent anti-HCV activity.

Anticipated Highlights

-- Initiating dosing and announcing preliminary results of Cohorts 3 and 4

in a 4-week combination study of R7128 with Pegasys plus Copegus for

the treatment of HCV in the third calendar quarter of 2008.

-- Completing HBV patient enrollment for clevudine Phase 3 registration

studies in the second calendar half of 2008.

-- Initiating trial activities for a global 12-week Phase 2b combination

study of R7128 with Pegasys plus Copegus in the fourth calendar quarter


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Neil Haley, the Total Tutor host of the Simply ... about the importance of capacity to grow a business. , ... and is now a 5 Star Ambassador, Vi Millionaire, and ... titled "The Playful and Powerful Warrior Within You!" and holds ... out for over 1000 days straight. He is also ...
(Date:8/27/2014)... York, NY (PRWEB) August 27, 2014 Overcoming ... failure, he finally found his niche. The Women’s Radio Network, ... Armstrong for his continued support and dedication to the WRNW1 ... be able to have such a positive atmosphere.” After KC ... on Sirius XM of the Howard Stern show, “Howard 100 ...
(Date:8/27/2014)... 2014 A recently published study ... of time in correcting coagulopathy to prevent permanent injury ... of anticoagulants and examines medical conditions alleged to be ... although anticoagulants have been approved by the FDA to ... are also known to affect the consistency of the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The use ... quality of life and may eliminate the need for ... During a recent AllMed webinar, Dr. Zanhua Yi, board ... related to determining medical necessity of erythropoiesis-stimulating agents (ESAs) ... (CKD). , The U.S. Food and Drug Administration (FDA) ...
(Date:8/27/2014)... August 27, 2014 iHire was ... as the “Most Creative Workplace” in Frederick, a ... Places to Work Awards. , Held at the ... is a joint partnership between the Frederick County ... Development, Frederick County Business Development and Retention, and ...
Breaking Medicine News(10 mins):Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:iHire Named Most Creative Workplace in Frederick, MD 2
... March 3, 2008 The International AIDS Vaccine Initiative ... Fund, a new funding mechanism that will identify and ... AIDS vaccine research field. This initial project will apply ... the size of a small coin, which has the ...
... a new genetic risk factor for coeliac disease, have, ... implicated in causing the condition. The team, lead by ... and The London School of Medicine and Dentistry, have ... now know, four of these are also predisposing factors ...
... March 2 Therap Services announces the,release of version ... applications. Therap version 7.2 will feature,new forms such as ... module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) form in ... 7.2 include: -- Behavior Plan and Behavior Event ...
... Incontinence, dropped organs not just a function of age, study ... women in the United States have one or more pelvic ... disorders, says a Kaiser Permanente study. , Frequent urge to ... of such disorders. , The study of 4,000 women (80 ...
... Md. and ST. PAUL, Minn., Feb. 29 /PRNewswire-USNewswire/,-- ... Society &,Family Services, application for full Hague Accreditation ... This achievement of Hague,Accreditation demonstrates CHSFS, commitment to ... and abroad., The Hague Convention on Protection ...
... OAKLAND, Calif., Feb. 29 California,s,largest nonprofit hospital ... negotiations Thursday covering 15,000 hospital,workers across California., ... of negotiations underway and,continue their joint efforts to ... services across the state. In 2004, Catholic Healthcare,West ...
Cached Medicine News:Health News:IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines 2Health News:Scientists uncover further steps leading to celiac disease 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:Pelvic Floor Disorders Affect 1 in 3 Women 2Health News:Children's Home Society & Family Services Achieves Full Hague Accreditation 2Health News:Catholic Healthcare West and SEIU Begin Negotiations for 15,000 Hospital Workers 2
(Date:8/27/2014)...  Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a ... be participating in the Morgan Stanley 2014 Global Healthcare ... York, New York , on Tuesday, September 9, ... Zimmer, will be presenting at 9:10 a.m. Eastern Time.  ... will join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
(Date:8/26/2014)... Malaysia , Aug. 27, 2014 ... health insurance are fuelling the demand for medical ... the rise of medical tourism, the inflow of ... increasing. The market will continue its steady ascent ... to age-related and non-communicable diseases, compelling significant investments ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4
Inquire...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
Medicine Products: